Comparison of the Effect of Omeprazole, Pantoprazole, Esomeprazole, and Lansoprazole on the Reduction of Symptoms in Patients with Gastroesophageal Reflux Disease

Document Type : Original Article (s)

Authors

1 Resident, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Iran

2 Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Iran

Abstract

Background: Gastroesophageal reflux disease (GERD) is a chronic and recurrence disease with increasing prevalence, and selection of the best treatment method has been considered for many years. Proton pump inhibitors (PPIs) are among the basic treatment of this disease; so this study aimed to evaluate the effects of omeprazole, pantoprazole, esomeprazole, and lansoprazole on the symptoms of GERD.Methods: This randomized clinical trial study was conducted on 120 patients with GERD. They were randomly divided into 4 groups of 30 and received 40 mg omeprazole, 40 mg pantoprazole, 40 mg esomeprazole, and 30 mg lansoprazole that administered as daily single fasting dose for 8 weeks. The severity of the symptoms of heart burn and regurgitation were signed in the form of a questionnaire (GERD-HRQL) at the time of the before study and at the 2nd, 4th, and 8th weeks of treatment. The collected data were analyzed and compared between the four groups using SPSS software.Findings: There was no significant difference in the mean of heart burn and regurgitation severity before intervention and during the 2nd, 4th, and 8th weeks of treatment between the four groups (P > 0.050). But, there were significant reductions in each group comparing these symptoms between the 0 and 8 weeks of treatment (P < 0.001).Conclusion: There is no significant difference between the four medications omeprazole, lansoprazole, esomeprazole, and pantoprazole in reducing GERD symptoms, and all of them could decrease the severity of general symptoms by time.

Keywords


  1. Abbasinazari M, Panahi Y, Mortazavi SA, Fahimi F, Valizadegan G, Mohtashami R, et al. Effect of a Combination of omeprazole plus sustained release baclofen versus omeprazole alone on symptoms of patients with gastroesophageal reflux disease (GERD). Iran J Pharm Res 2014; 13(4): 1221-6.
  2. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol 2006; 101(8): 1900-20.
  3. Eisen G. The epidemiology of gastroesophageal reflux disease: what we know and what we need to know. Am J Gastroenterol 2001; 96(8 Suppl): S16-S18.
  4. Damiano A, Handley K, Adler E, Siddique R, Bhattacharyja A. Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: Further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS). Dig Dis Sci 2002; 47(7): 1530-7.
  5. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340(11): 825-31.
  6. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108(3): 308-28.
  7. Delavari A, Moradi G, Birjandi F, Elahi E, Saberifiroozi M. The prevalence of gastroesophageal reflux disease (GERD) in the Islamic Republic of Iran: A systematic review. Middle East J Dig Dis 2012; 4(1): 5-15.
  8. Farup C, Kleinman L, Sloan S, Ganoczy D, Chee E, Lee C, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001; 161(1): 45-52.
  9. Jung SH, Oh JH, Jie BS, Oh SH, Kim JS, Jeon JS, et al. Typical symptoms rather than extraesophageal symptoms affect the quality of life in gastroesophageal reflux disease. Turk J Gastroenterol 2012; 23(6): 747-52.
  10. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine. 19th ed. New York, NY: McGraw-Hill Education; 2015.
  11. Velanovich V. The development of the GERD-HRQL symptom severity instrument. Dis Esophagus 2007; 20(2): 130-4.
  12. Hunter JG, Trus TL, Branum GD, Waring JP, Wood WC. A physiologic approach to laparoscopic fundoplication for gastroesophageal reflux disease. Ann Surg 1996; 223(6): 673-85.
  13. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98(7): 1487-93.
  14. Chait MM. Gastroesophageal reflux disease: Important considerations for the older patients. World J Gastrointest Endosc 2010; 2(12): 388-96.
  15. Tack J. Emerging medical therapies for the treatment of GERD. Gastroenterol Hepatol (NY) 2010; 6(9): 566-9.
  16. Wang YK, Hsu WH, Wang SS, Lu CY, Kuo FC, Su YC, et al. Current pharmacological management of gastroesophageal reflux disease. Gastroenterol Res Pract 2013; 2013: 983653.
  17. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17(2): 243-51.
  18. van Herwaarden MA, Samsom M, Rydholm H, Smout AJ. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002; 16(9): 1655-62.
  19. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997; 112(6): 1798-810.
  20. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011; 106(8): 1419-25.
  21. Ip S, Chung M, Moorthy D, Yu WW, Lee J, Chan JA, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease: Update. Rockville, MD: Agency for Healthcare Research and Quality (US); 2011.
  22. Nasseri Moghaddam S, Tofangchiha S, Azimi K, Ostad Rahimi S, Malekzade R. Comparing different brands of omeprazole with Pantozole® in GERD patients. Ann Mil Health Sci Res 2010; 8 (2): 132-7. [In Persian].
  23. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96(3): 656-65.
  24. Coron E, Hatlebakk JG, Galmiche JP. Medical therapy of gastroesophageal reflux disease. Curr Opin Gastroenterol 2007; 23(4): 434-9.
  25. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96(1): 27-34.
  26. Remak E, Brown RE, Yuen C, Robinson A. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK. Curr Med Res Opin 2005; 21(10): 1505-17.
  27. Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci 2000; 45(5): 845-53.
  28. Janczewska I, Sagar M, Sjostedt S, Hammarlund B, Iwarzon M, Seensalu R. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33(12): 1239-43.
  29. Stedman CA, Barclay ML. Review article: Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14(8): 963-78.